Recent studies have sought to evaluate early oncogenic signaling in EGFR-mutant lung cancers under EGFR-TKI treatment, but few studies have evaluated the effect of the tumor microenvironment on persistent tumor cells under EGFR-TKI treatment. This evidence concerns the gene EGFR and neoplasm.